Ardelyx, Inc. (ARDX)
Develops medications treating irritable bowel syndrome and kidney disease complications.
$5.09+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+17.4%
The outlook
Analysts rate ARDX as a Strong Buy, with an average price target about 221% above the current price. The stock is trading well below both its 50- and 200-day moving averages and sits near the lower end of its 52-week range. The overall sentiment is neutral despite the bullish analyst view, reflecting a disconnect between analyst expectations and current market positioning.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 10 analysts
Price trendBelow its 50- & 200-day averages
52-week range23% of the way from its 52-week low to high
Price targetAvg target +221% vs current price
Analyst price target
~12-month · 10 analysts$16.30average target+220.6% vs now
Now $5.09
Low $13.00High $19.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.26B
52-wk high
$8.40
52-wk low
$4.08
50-day avg
$5.64
200-day avg
$6.03
Trailing P/E
—